About this trial
The incidence of esophagogastric junction has been increasing in recent years, and surgery is an important method for the treatment of adenoma at the esophagogastric junction. Currently, there is a great controversy about the surgical method of Siewert II, mainly choosing the right chest or the left chest for thoracic surgery. Therefore, it is of great significance to further study the surgical methods of Siewert II esophagogastric junction adenoma. Objective: To compare the safety, feasibility, and clinical efficacy of endoscopic Ivor-Lewis versus laparoscopic extended abdominal gastrectomy for Siewert type Ⅱadenocarcinoma at the resectable esophagogastric junction.
Eligibility criteria
Qualifiers
Histologically confirmed EGJ type II adenocarcinoma
Pretreatment stage CT1-4A, N0-3, M0
For cT4a stage patients, their resectable properties must be clearly verified before randomization
For locally advanced tumors (CT3-T4 or N+), all 4 cycles of chemotherapy (FLOT) were completed before surgery.
Disqualifiers
Histologically confirmed EGJ type I and III adenocarcinoma
Tumor spread over 5 cm proximal to EGJ
Clinically significant (active) heart disease (i.e. symptomatic coronary artery disease or myocardial infarction within the last 12 months) resulting in left ventricular ejection fraction<50%(determined by echocardiography)
Clinically significant lung diseases (forced expiratory volume in 1 second (FEV1)<1.5 l/s)
Trial design
Treatments tested in this trial
- Endoscopy Ivor-lewis
- Laparoscopic transabdominal enlarged gastrectomy
Treatment groups
Sponsors and collaborators
Xijing Hospital of Digestive Diseases
Lead sponsor
Tang-Du Hospital
Collaborator
Henan Provincial People's Hospital
Collaborator
General Hospital of Ningxia Medical University
Collaborator
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
The First Affiliated Hospital of Shanxi Medical University
Collaborator